Clinical Highlights from the 2020 Midyear: Controversies Surrounding Antithrombotic Therapy Following Transcatheter Aortic Valve Replacement

Join our content matter expert from Section of Ambulatory Care Practitioners at the 2020 Midyear Clinical Meeting as they compare appropriate antithrombotic regimens for patients with and without atrial fibrillation who have recently undergone transcatheter aortic valve replacement (TAVR), evaluate the role of dual antiplatelet therapy (DAPT) in patients who have recently undergone TAVR and summarize the prevention and treatment of subclinical leaflet thrombosis in these patients.

The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.